4.7 Article

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo

Journal

CLINICAL CANCER RESEARCH
Volume 24, Issue 16, Pages 4030-4043

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-17-3167

Keywords

-

Categories

Funding

  1. NIH [DK075140]
  2. NATIONAL CANCER INSTITUTE [ZIABC008752, ZIABC011275] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075035, ZIADK075140] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose: Mitochondrial glycerophosphate dehydrogenase (MGPDH) is the key enzyme connecting oxidative phosphorylation (OXPHOS) and glycolysis as well as a target of the antidiabetic drug metformin in the liver. There are no data on the expression and role of MGPDH as a metformin target in cancer. In this study, we evaluated MGPDH as a potential target of metformin in thyroid cancer and investigated its contribution in thyroid cancer metabolism. Experimental Design: We analyzed MGPDH expression in 253 thyroid cancer and normal tissues by immunostaining and examined its expression and localization in thyroid cancer-derived cell lines (FTC133, BCPAP) by confocal microscopy. The effects of metformin on MGPDH expression were determined by qRT-PCR and Western blot analysis. Seahorse analyzer was utilized to assess the effects of metformin on OXPHOS and glycolysis in thyroid cancer cells. We analyzed the effects of metformin on tumor growth and MGPDH expression in metastatic thyroid cancer mouse models. Results: We show for the first time that MGPDH is overexpressed in thyroid cancer compared with normal thyroid. We demonstrate that MGPDH regulates human thyroid cancer cell growth and OXPHOS rate in vitro. Metformin treatment is associated with downregulation of MGPDH expression and inhibition of OXPHOS in thyroid cancer in vitro. Cells characterized by high MGPDH expression are more sensitive to OXPHOS-inhibitory effects of metformin in vitro and growth-inhibitory effects of metformin in vitro and in vivo. Conclusions: Our study established MGPDH as a novel regulator of thyroid cancer growth and metabolism that can be effectively targeted by metformin. (C) 2018 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin

Summary: The study reported a case of a patient who developed symptomatic primary hypothyroidism after receiving Lu-177-DOTATATE therapy, with notable changes in TFTs and thyroid auto-antibody titers before and after treatment. Functional imaging revealed diffuse uptake of Lu-177-DOTATATE in the thyroid gland.

FRONTIERS IN ENDOCRINOLOGY (2021)

Letter Medicine, General & Internal

Combined Immunosuppressive Therapy for Severe Graves Dermopathy

Sriram Gubbi, Katherine Andrea Araque, Shirisha Avadhanula, Asma Azam, Roxanne Merkel, Craig Cochran, Peter Denis Burbelo, Meryl Waldman, Susanne Neumann, Marvin Carl Gershengorn, Monica Skarulis, Joanna Klubo-Gwiezdzinska

ANNALS OF INTERNAL MEDICINE (2021)

Article Endocrinology & Metabolism

Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin

Dorina Ylli, Steven J. Soldin, Brian Stolze, Bin Wei, Girum Nigussie, Hung Nguyen, Damodara Rao Mendu, Mihriye Mete, Di Wu, Cristiane J. Gomes-Lima, Joanna Klubo-Gwiezdzinska, Kenneth D. Burman, Leonard Wartofsky

Summary: This study found that biotin intake can lead to variations in thyroid-related laboratory test results, especially in data measured on the Roche Cobas 6000 and Siemens IMMULITE 2000 platforms. Taking 10 mg of biotin per day can interfere with the measurement results of specific indices such as TSH, fT4, TT3, and Tg.

THYROID (2021)

Editorial Material Endocrinology & Metabolism

Targeting RET-mutated thyroid and lung cancer in the personalised medicine era

Joanna Klubo-Gwiezdzinska

LANCET DIABETES & ENDOCRINOLOGY (2021)

Article Endocrinology & Metabolism

Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays

Christine C. Krieger, George J. Kahaly, Asma Azam, Joanna Klubo-Gwiezdzinska, Susanne Neumann, Marvin C. Gershengorn

Summary: The study found a positive correlation between TSAb stimulation of cAMP production in engineered cells and secretion of TG by thyrocytes and HA by orbital fibroblasts. TSAbs from GH patients stimulated thyrocytes more effectively than those from GO patients, while TSAbs from GO patients were more effective in activating orbital fibroblasts than TSAbs from GH patients.

THYROID (2022)

Article Oncology

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan

Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Endocrinology & Metabolism

Hypertension and COVID-19: Updates from the era of vaccines and variants

Sowmya Swamy, Christian A. Koch, Fady Hannah-Shmouni, Ernesto L. Schiffrin, Joanna Klubo-Gwiezdzinska, Sriram Gubbi

Summary: Older age and certain components of metabolic syndrome (including hypertension) have been associated with an increased risk of severe illness and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied.

JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2022)

Review Endocrinology & Metabolism

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors

Sriram Gubbi, Namrata Vijayvergia, Jian Q. Yu, Joanna Klubo-Gwiezdzinska, Christian A. Koch

Summary: Neuroendocrine tumors (NETs) have complex clinical and biochemical characteristics, and their molecular basis is not fully understood. The treatment of NETs involves surgery, locoregional therapy, and systemic therapy. Although various forms of systemic therapy have been extensively studied, the use of immune checkpoint inhibitors (ICI) in the management of NETs has only recently received attention. It is currently unclear whether ICI therapy provides any distinct advantages in terms of efficacy or safety compared to other available systemic therapies. Identifying the characteristics of NETs that would make them more responsive to ICI therapy has been challenging.

HORMONE AND METABOLIC RESEARCH (2022)

Letter Endocrinology & Metabolism

Response to Letter to the Editor from Zandee and Links: Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration

Cristiane J. Gomes-Lima, Sanjita Chittimoju, Leen Wehbeh, Sunita Dia, Prathyusha Pagadala, Mohammad Al-Jundi, Sakshi Jhawar, Eshetu Tefera, Mihriye Mete, Joanna Klubo-Gwiezdzinska, Douglas Van Nostrand, Jacqueline Jonklaas, Leonard Wartofsky, Kenneth D. Burman

JOURNAL OF THE ENDOCRINE SOCIETY (2023)

Article Endocrinology & Metabolism

Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression

Johannes F. Fahrmann, Amanda R. Wasylishen, Carolina R. C. Pieterman, Ehsan Irajizad, Jody Vykoukal, Ranran Wu, Jennifer B. Dennison, Christine B. Peterson, Hua Zhao, Kim-Anh Do, Daniel M. Halperin, Sunita K. Agarwal, Jenny E. Blau, Smita Jha, Jaydira Del Rivero, Naris Nilubol, Mary F. Walter, James M. Welch, Lee S. Weinstein, Menno R. Vriens, Rachel S. van Leeuwaarde, Mark J. C. van Treijen, Gerlof D. Valk, Nancy D. Perrier, Samir M. Hanash, Hiroyuki Katayama

Summary: This study identified novel circulating protein markers associated with disease progression in MEN1-related dpNET through mass spectrometry-based proteomic profiling.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Article Endocrinology & Metabolism

Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome

Rana Tora, James Welch, Jian Sun, Sunita K. Agarwal, Debra A. Bell, Maria Merino, Lee S. Weinstein, William F. Simonds, Smita Jha

Summary: This study retrospectively characterized HPT-JT syndrome and found an increased risk of parathyroid cancer associated with the disease. The study also identified a correlation between HPT-JT and uterine tumors and kidney tumors, and investigated the mutations of the CDC73 gene.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Article Endocrinology & Metabolism

Long-Term Outcomes of Parathyroid Autografts in Primary Hyperparathyroidism

Elias Chuki, Akua Graf, Anisha Ninan, Rana Tora, Tomilowo Abijo, Lynn Bliss, Naris Nilubol, Lee S. Weinstein, Sunita K. Agarwal, William F. Simonds, Smita Jha

Summary: Long-term outcomes of parathyroid autografts in patients with heritable forms of primary hyperparathyroidism (PHPT) were investigated. The study found that post-graft recurrence of PHPT occurs frequently within the first decade after graft and is challenging to localize, with graft-related recurrences having a shorter time to recurrence and higher parathyroid hormone (PTH) gradient.

JOURNAL OF THE ENDOCRINE SOCIETY (2023)

Article Endocrinology & Metabolism

A Knock-In Mouse Model of the Gcm2 Variant p.Y392S Develops Normal Parathyroid Glands

Vaishali Parekh, Lauren R. Brinster, Bin Guan, William F. Simonds, Lee S. Weinstein, Sunita K. Agarwal

Summary: This study used CRISPR/Cas9 gene editing technology to generate a mouse model carrying the GCM2 p.Y392S variant. The results showed that this variant is tolerated in mice and does not increase parathyroid gland cell proliferation or circulating calcium or PTH levels. Further investigation of this variant in early events of parathyroid gland development will be interesting.

JOURNAL OF THE ENDOCRINE SOCIETY (2023)

Article Endocrinology & Metabolism

Mice With RIP-Cre-mediated Deletion of the Long Noncoding RNA Meg3 Show Normal Pancreatic Islets and Enlarged Pituitary

Vaishali Parekh, Hui Sun, Min Chen, Lee S. Weinstein, Sunita K. Agarwal

Summary: The loss of Meg3 gene leads to hyperplasia in the pituitary but not in pancreatic islets, serving as a valuable model to study pathways associated with pituitary cell proliferation and function.

JOURNAL OF THE ENDOCRINE SOCIETY (2022)

Article Endocrinology & Metabolism

Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors

Akua Graf, James Welch, Rashika Bansal, Adel Mandl, Vaishali Parekh, Craig Cochran, Elliot Levy, Naris Nilubol, Dhaval Patel, Samira Sadowski, Smita Jha, Sunita K. Agarwal, Corina Millo, Jenny E. Blau, William F. Simonds, Lee S. Weinstein, Jaydira Del Rivero

Summary: This article reports a case of a patient with MEN1 who has a rare and aggressive G3 GEP-NET. Due to limited treatment recommendations for G3 tumors in MEN1, the patient was counseled based on standard NET treatment guidelines and recommended Lu-177-DOTATATE treatment.

JOURNAL OF THE ENDOCRINE SOCIETY (2022)

No Data Available